Member Info for Krone

Potnak - your enforced absence seems to have focused your mind somewhat and I am in wholehearted agreement.

Wheels within wheels…..

Some interesting updates yesterday....https://investor.sierraoncology.com/financials/sec-filings/default.aspx
Do we know if UK based Abingworth LLP have a position in Sareum?
https://d18rn0p25nwr6d.cloudfront.net/CIK-0001290149/865ed619-6bdf-4211-b8d4-01388e388c93.pdf

"We continue to evaluate additional studies and may initiate other new trials for SRA515 and SRA737 in 2022."
https://investor.sierraoncology.com/news-releases/news-details/2021/Sierra-Oncology-Reports-Third-Quarter-2021-Results/default.aspx

https://twitter.com/medistrava_cons/status/1455562243286896649?s=21

A great opportunity for Medistrava to fly the Sareum flag…capsules, covid, ARDS, lupus etc etc ….whether they take it remains to be seen.

And one more....
https://endpts.com/roche-ateas-covid-19-pill-fails-mid-stage-trial-clouding-future-for-closely-watched-program/

In adults hospitalised with COVID-19, colchicine was not associated with reductions in 28-day mortality, duration of hospital stay, or risk of progressing to invasive mechanical ventilation or death.
https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(21)00435-5/fulltext#.YW7YTRIyM9w.twitter

RMM - how does this impact on your current valuations?

Including SRA737 ?
https://endpts.com/astrazeneca-oncology-rd-chief-susan-galbraith-youre-going-to-need-orthogonal-combinations/

Hotblack - Absolutely, much bigger fish to fry!

http://www.sareum.com/news/events/
http://events.ebdgroup.com/bioeurope/core/participating-companies2021.php?_ga=2.15439029.2053501302.1634199133-1685884432.1634199132
Apparently not participating....?

http://www.sareum.com/news/press-releases-and-news/2020/research-update/

https://twitter.com/medistrava_cons/status/1446147591318777867?s=21

Hoping all goes well.

We’ve come a long way in 12 months…

SDC-1801 has demonstrated excellent tolerability in initial toxicology studies in rodents. A formulation that is predicted to deliver a therapeutic dose level has also been identified.

· If progress is successful, the application to commence first human trials is expected to be made during Q1 2021.

SDC-1802 (cancer immunotherapy)

· Formulation work for oral dosing of SDC-1802 is complete and toxicology studies and further manufacturing work are planned over the coming months.

· In October 2019, Sareum presented new findings showing that SDC-1802, dosed orally as a monotherapy and in combination with chemotherapy, significantly reduces tumour growth in models of solid tumours and blood cancers.

· In October 2020, the Company received a Notice of Allowance for its US patent covering SDC-1802, the grant of which will complete the patent protection of this compound in all major territories.

TYK2/JAK1 Inhibitors for treating symptoms of Covid-19

· A grant application has been submitted to UK Research and Innovation (UKRI) to fund preliminary laboratory studies investigating the potential of Sareum's TYK2/JAK1 inhibitors to address the severe inflammatory responses (the "cytokine storm") and potentially fatal respiratory symptoms of Covid-19 and other viral infections.

· A response is expected by the end of October 2020 which, if successful, will enable initial studies to begin shortly thereafter.

Given that the final results for the last 4 years have been presented between the end of September and first weeks of October it is reasonable to expect an RNS any day. It will telling if the results are delayed and/or if there is no IMC presentation announced.

GlaxoSmithKline, Merck KGaA officially call it quits on $4B partnership for flailing cancer drug…
SDC-1802….come on down.
https://endpts.com/glaxosmithkline-merck-kgaa-officially-call-it-quits-on-4b-partnership-for-flailing-cancer-drug/

Thoth - are we expecting an RNS on this today?

Ooops, apols, appears that the combination study referred to was previously published https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.15_suppl.3095